Novel Therapies for the Treatment of Cardiovascular Disease.
Humans
Cardiovascular Diseases
/ drug therapy
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Heart Failure
/ drug therapy
Cardiovascular Agents
/ therapeutic use
Hypertension
/ drug therapy
Antihypertensive Agents
/ therapeutic use
Ivabradine
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Aminobutyrates
/ therapeutic use
Angiotensin Receptor Antagonists
/ therapeutic use
Valsartan
Dicarboxylic Acids
Fatty Acids
RNA, Small Interfering
Cardiology
Heart failure
Ivabradine
SGLT2 inhibitors
Sacubitril-valsartan
Journal
The Medical clinics of North America
ISSN: 1557-9859
Titre abrégé: Med Clin North Am
Pays: United States
ID NLM: 2985236R
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
31
7
2024
Statut:
ppublish
Résumé
Over the last decade, randomized clinical trials of several pharmacologic agents have demonstrated a reduction in cardiovascular mortality and other important secondary outcomes. Angiotensin-Neprilysin Inhibitors and Sodium-Glucose Co-transporter 2 inhibitors have now become pillars in the treatment of heart failure. Ivabradine is a negative chronotropic agent used as an adjunctive therapy in patients with heart failure. Two new hypertension therapies, zilebresiran and aprocitentan, are currently in investigational stages. Finally, mavacamten has emerged as a pharmacologic treatment for hypertrophic obstructive cardiomyopathy. Practitioners must be familiar with the indications and side effects of newer therapies as they are now frequently prescribed.
Identifiants
pubmed: 39084843
pii: S0025-7125(24)00020-8
doi: 10.1016/j.mcna.2024.03.003
pii:
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Cardiovascular Agents
0
Antihypertensive Agents
0
Ivabradine
3H48L0LPZQ
Angiotensin-Converting Enzyme Inhibitors
0
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
1EJ6Z6Q368
Aminobutyrates
0
Angiotensin Receptor Antagonists
0
Valsartan
80M03YXJ7I
ALN-PCS
0
Dicarboxylic Acids
0
Fatty Acids
0
RNA, Small Interfering
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
953-964Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.